Wagstaff Kylie M, Jans David A
Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia.
Biochem J. 2007 Sep 1;406(2):185-202. doi: 10.1042/BJ20070505.
Gene therapy, the correction of dysfunctional or deleted genes by supplying the lacking component, has long been awaited as a means to permanently treat or reverse many genetic disorders. To achieve this, therapeutic DNA must be delivered to the nucleus of cells using a safe and efficient delivery vector. Although viral-based vectors have been utilized extensively due to their innate ability to deliver DNA to intact cells, safety considerations, such as pathogenicity, oncogenicity and the stimulation of an immunological response in the host, remain problematical. There has, however, been much progress in the development of safe non-viral gene-delivery vectors, although they remain less efficient than the viral counterparts. The major limitations of non-viral gene transfer reside in the fact that it must be tailored to overcome the intracellular barriers to DNA delivery that viruses already master, including the cellular and nuclear membranes. In particular, nuclear transport of the therapeutic DNA is known to be the rate-limiting step in the gene-delivery process. Despite this, much progress had been made in recent years in developing novel means to overcome these barriers and efficiently deliver DNA to the nuclei of intact cells. This review focuses on the nucleocytoplasmic delivery of DNA and mechanisms to enhance to non-viral-mediated gene transfer.
基因治疗,即通过提供缺失的成分来纠正功能失调或缺失的基因,长期以来一直被视作一种永久治疗或逆转多种遗传疾病的手段。要实现这一目标,必须使用安全有效的递送载体将治疗性DNA递送至细胞的细胞核。尽管基于病毒的载体因其将DNA递送至完整细胞的固有能力而被广泛应用,但诸如致病性、致癌性以及在宿主中引发免疫反应等安全性问题仍然存在。然而,安全的非病毒基因递送载体的开发已取得了很大进展,尽管它们的效率仍低于病毒载体。非病毒基因转移的主要局限性在于,它必须经过调整以克服病毒已经掌握的DNA递送的细胞内障碍,包括细胞膜和核膜。特别是,治疗性DNA的核转运是基因递送过程中的限速步骤。尽管如此,近年来在开发克服这些障碍并将DNA有效递送至完整细胞核的新方法方面已取得了很大进展。本综述重点关注DNA的核质递送以及增强非病毒介导的基因转移的机制。